Trial Profile
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Ivacaftor/tezacaftor/VX-659 (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 06 Mar 2019 According to a Vertex Pharmaceuticals media release, 24 week data from this study which included patients with one F508del mutation and one minimal function mutation is expected in the second quarter of 2019.
- 06 Mar 2019 Status changed from active, no longer recruiting to completed.
- 27 Nov 2018 Results presented in a Vertex Pharmaceuticals media release.